Ivabradine Anpharm

Ivabradine, the active ingredient in Ivabradine Anpharm, is a If channel inhibitor presented as a tablet for oral use. It reduces heart rate without affecting myocardial contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients, particularly in patients with coronary artery disease.

GNH USA supplies Ivabradine Anpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Ivabradine is used to manage conditions related to myocardial oxygen demand and heart rate regulation.

- Chronic stable angina: improves exercise tolerance by lowering heart rate without reducing contractility. - Heart failure with reduced ejection fraction: decreases hospitalization risk by reducing heart rate in symptomatic patients.

Ivabradine may be associated with several adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: symptomatic slowing of heart rate. - Headache: mild to moderate intensity. - Dizziness: especially upon standing.

Serious or Rare Side Effects: - Atrial fibrillation: new‑onset arrhythmia. - Severe hypotension: marked blood pressure drop. - Vision loss: rare persistent visual impairment.

Before prescribing ivabradine, clinicians should consider several precautionary measures to ensure safe use.

- Contraindication: severe hepatic impairment. - Caution: patients with pre‑existing bradycardia. - Monitoring: heart rate should be checked after dose adjustments. - Interaction: avoid concomitant strong CYP3A4 inhibitors. - Pregnancy: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Ivabradine can interact with other medicines, influencing its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels and risk of bradycardia. - Concomitant use with other heart‑rate‑lowering agents (e.g., beta‑blockers, digoxin) without monitoring: can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antidepressants affecting cardiac conduction (e.g., amiodarone): requires ECG monitoring.